Economy and Health ministries move to secure high‑risk drugs and devices through stockpiles, new suppliers and faster import pathways.
Malaysia is tightening oversight of medicine and medical device supplies as global crises strain supply chains, with new stockpiles, diversified sourcing and price-transparency measures to keep essential care affordable and available.
Current Supply Status And Risk Levels
Economy Minister Akmal Nasrullah Mohd Nasir said on May 25 that data as at May 8 show overall medicine supplies remain “stable and sufficient”: about 72 per cent of medical items are widely available, 11.3 per cent are at medium risk of shortage, and 16.8 per cent are categorised as high risk requiring close monitoring. For medical devices, 81 per cent are available, 13 per cent are at medium risk and 4 per cent are high risk.
Task Force Monitoring And National Stockpiling
Although high‑risk items are currently stable, Akmal said a special task force will regularly track stocks, supported by immediate national stockpiling of critical medicines. Continuous monitoring and mitigation are intended to ensure that any emerging bottlenecks are detected early, reducing the chance that patients and hospitals face sudden shortages of life‑saving drugs or essential equipment.
Diversifying Foreign Supply Sources
To reduce dependence on any single source, Malaysia is diversifying supply through strategic agreements with other countries, including China and Uzbekistan, and a new pact with Japan to be formalised during the Prime Minister’s visit. Akmal said these moves are designed to strengthen resilience across key product lines that are exposed to global disruptions.
Faster Import Approvals For Critical Drugs
The government will also introduce a Special Access Pathway to expedite regulatory approval for importing critical medicines during shortages, cutting red tape when urgent access is needed. In parallel, the Health Ministry is working to develop local industry capabilities, particularly in medical device manufacturing, to reduce long‑term reliance on imports and build more secure domestic production.
Managing Costs And Ensuring Price Transparency
Akmal noted that any cost adjustments arising from supply measures will be targeted based on actual needs and risk levels, rather than across-the-board increases. He urged the Health Ministry to step up efforts to ensure price transparency for medicines sold in pharmacies, so the public is not burdened by unreasonable mark‑ups and can better compare prices for the treatments they need.
Malaysia’s latest steps—tighter monitoring, strategic stockpiles, diversified sourcing, faster import channels and local industry development—aim to shield patients and hospitals from global supply shocks while keeping essential medicines affordable. For Indonesians and Singaporeans, they highlight how proactive, data‑driven planning and price transparency can help health systems stay resilient when international supply chains come under strain.
Sources: Straits Times (2026) , The Star (2026)
Keywords: High Risk Medicines, National Stockpile, Special Access Pathway, Diversified Supply Sources, Akmal Nasrullah
